Latest Breaking News On - Quarter ended september - Page 5 : comparemela.com

Talon Metals Reports Results for the Quarter Ended September 30, 2023

Talon Metals Corp. reported a net loss for the three months ended 30, 2023 of $0.5 million or nil per share , which was primarily the result of administration expenses. This compares to net income for the three months ended 30, 2022 of $0.5 million. - Veroeffentlicht am 13.11.2023

United statesSean wergerTalon metals corpUs department of defenseUs department of energyTesla incRio tintoTalon metals reports resultsQuarter ended septemberTamarack nickel copper cobalt projectInterim consolidated financial statementsTamarack nickel projectTamarack intrusiveUnited steelworkersBattery mineral processing facilityMercer county

Theriva™ Biologics Reports Third Quarter 2023 Operational Highlights and Financial Results

- VIRAGE, the Phase 2b clinical trial of VCN-01 in combination with chemotherapy for metastatic Pancreatic Ductal Adenocarcinoma remains on track .

United statesSan diegoStevena shallcrossChris calabreseInstitut catalaRicard mesiaMd institut catalTheriva biologicsEuropean society for medical oncologySociety for immunotherapy of cancerCompany annual report on formLifesci advisorsNet loss attributable to theriva biologics incOncologia catalan institute of oncologyUniversity of pennsylvaniaPancreatic ductal adenocarcinoma

Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives

Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesNasdaq stock marketCompany nasdaqExchange commissionCantor fitzgerald coAlaunos therapeutics incCompany library phaseAlaunos therapeutics inc statement of operationsLibrary phaseAlaunos therapeutics inc selected balance sheet dataNational cancer instituteDevelopment expensesCantor fitzgeraldSleeping beautyPlatform identifies proprietaryQuarter ended september

Alaunos Therapeutics (TCRT) Reports Q3, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives

Alaunos Therapeutics (TCRT) Reports Q3, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Alaunos therapeutics inc selected balance sheet dataNational cancer instituteDevelopment expensesAlaunos therapeutics incCantor fitzgerald coNasdaq stock marketAlaunos therapeutics inc statement of operationsLibrary phaseCompany nasdaqCompany library phaseExchange commissionAlaunos therapeuticsCantor fitzgeraldSleeping beautyPlatform identifies proprietaryQuarter ended september

Alaunos Therapeutics Announces Third Quarter 2023 Financial

TCR-T Library Phase 1/2 trial achieved an 87% disease control rate of eight evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy.

United statesNational cancer instituteCompany nasdaqLibrary phaseNasdaq stock marketAlaunos therapeutics incCompany library phaseDevelopment expensesCantor fitzgerald coExchange commissionCantor fitzgeraldSleeping beautyPlatform identifies proprietaryQuarter ended septemberSolasia licenseCollaboration agreement